Companies often arrive at a payer meeting with the materials they use for physicians: mechanism of action, trial highlights, a strong headline. Payers sit through it politely. Then they ask their own questions, and the meeting really begins.
Those questions vary by system, but most come back to a short list.
1. Which patients, exactly?
Not the indication on the label. The patients who will actually receive the medicine in their system. How are they identified? What criteria separate them from patients who should stay on current care? A vague population means an unpredictable budget, and an unpredictable budget is a reason to wait.
2. Compared with what?
Payers judge a medicine against what they fund today, not against placebo. If your trial comparator is not the local standard of care, expect to be asked how the result translates.
3. How certain are you?
Every new medicine carries uncertainty: short follow-up, surrogate endpoints, small subgroups. Payers do not expect certainty. They expect you to be honest about where it is missing and to have thought about how to manage it.
4. What will it cost us, and what will it save?
This is the budget question, framed for their population and their prices. Savings elsewhere in the system matter only if they are believable and land in a budget the payer controls.
5. What happens if we say yes?
Implementation is a real concern. Who prescribes? Where is it dispensed? How will the payer know it is used in the right patients? Proposals that make this easier are often more persuasive than another slide of efficacy data.
A payer is not your customer in the usual sense. They are a steward of a fixed budget who must defend every decision.
Preparing differently
The practical lesson is to build the payer conversation from these questions backwards. Start with population, comparator, uncertainty, budget and implementation. Put the clinical story in service of those answers. A payer who feels you understand their constraints will spend the meeting working on the problem with you rather than testing you.